Item 5. Other Information
ITEM 5. OTHER INFORMATION
(a) Disclosure in lieu of reporting on a Current Report on Form 8-K.
None.
(b) Material changes to the procedures by which security holders may recommend nominees to the board of directors.
None.
(c) Insider Trading Arrangements and Policies.
On January 8, 2026 , Rahsaan Thompson , our Chief Legal Officer, Secretary and Compliance Officer , adopted a Rule 10b5-1 trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 36,351 shares of our common stock. The plan will terminate at the earlier of the execution of all trading orders under the plan or January 9, 2027 .
On March 16, 2026 , Adrian W. Quartel , our Chief Medical Officer , adopted a Rule 10b5-1 trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 225,000 shares of our common stock. The plan will terminate at the earlier of the execution of all trading orders under the plan or April 30, 2027 .
On March 25, 2026 , Neil F. McFarlane , our President and Chief Executive Officer , adopted a Rule 10b5-1 trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to (i) 144,999 shares of our common stock and (ii) such number of shares of our common stock that may vest, subject to the achievement of certain performance goals, under performance-based restricted stock units (“PSUs”) for 72,500 shares of our common stock granted to Mr. McFarlane on February 7, 2025. The plan will terminate at the earlier of the execution of all trading orders under the plan or June 23, 2027 .
Other than as discussed above, during the three months ended March 31, 2026, no director or officer of Zevra adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
43
Table of Contents
ITEM 6. EXHIBITS
The following is a list of exhibits filed as part of this Form 10-Q (the SEC file number for all items incorporated by reference herein from reports on Forms 10-K, 10-Q, and 8-K is 001-36913):
Exhibit No. Description
3.1 Restated Certificate of Incorporation of Zevra Therapeutics, Inc. (incorporated herein by reference to the Registrant’s Annual Report on Form 10-K as filed with the SEC on March 9, 2026).
3.2 Amended and Restated Bylaws, as currently in effect, of Zevra Therapeutics, Inc. (incorporated herein by reference to the Registrant's Current Report on Form 8-K as filed with the SEC on February 28, 2024).
4.1 Specimen stock certificate evidencing shares of Common Stock (incorporated herein by reference to the Registrant's Annual Report on Form 10-K as filed with the SEC on March 12, 2021).
10.1*+#
Asset Purchase and Settlement Agreement , dated March 13, 2026 , by and between Zevra Therapeutics, Inc. and Commave Therapeutics SA .
10.2!
E mployment Agreement, effective as of March 9, 2026, by and betw een Zevra Therapeutics, Inc. and Justin Renz (incorporated by reference to the Registrant's Current Report on Form 8-K as filed with the SEC on March 9, 2026 ) .
10.3*+#
L ease, effective as of M arch 31, 2026, by and between 75-101 F ed Owner , L.L.C. and Zevra Therapeutics, Inc.
10.4*!
F irst Amendment, dated January 29, 2026, to the Employment Agreement, dated October 10, 2023 , as amended , by and between Neil McFarlane and Zevra Therap eutics, Inc.
10.5*!
First Amendment, dated January 29, 2026, to the Employment Agreement, dated January 23, 2024 , by and between Adrian Quartel and Zevra Therapeutics, Inc.
10.6*!
First Amendment, dated January 29, 2026, to the Employment Agreement, dated January 6, 2023 , by and between Joshua Schafer and Zevra Therapeutics, Inc.
10.7*!
First Amendment, dated January 29, 2026, to the Employment Agreement, dated June 20, 2024 , by and between Rahsaan Thompson and Zevra Therapeutics, Inc.
31.1* Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2* Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1** Certification of the Principal Executive Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18. U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2** Certification of the Principal Financial Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18. U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS* Inline XBRL Instance Document
101.SCH* Inline XBRL Taxonomy Extension Schema Document
101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document
104** Cover page Interactive Data File (embedded within the Inline XBRL and combined in Exhibit 101)
*
Filed herewith
**
Furnished herewith
!
Management contract or compensatory plan
+ Certain portions of the exhibit, identified by the mark, “[***]”, have been omitted because such portions contained information that is both (i) not material and (ii) the type that the Company treats as private or confidential
#
Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished to the Securities and Exchange Commission upon request; provided, however, that the parties may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any document so furnished
44
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Zevra Therapeutics, Inc.
Date: May 6, 2026 By: /s/ Neil F. McFarlane
Neil F. McFarlane
President and Chief Executive Officer
(Principal Executive Officer)
Date: May 6, 2026 By: /s/ Justin Renz
Justin Renz
Chief Financial Officer and Treasurer
(Principal Financial Officer)
45